Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-08
2009-10-13
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S292000, C546S198000, C546S199000
Reexamination Certificate
active
07601734
ABSTRACT:
An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of α2C-adrenoceptor and is useful in preventing and treating disorders attributable to α2C-adrenoceptor.The above-described object is solved by the following cyclic amine compound, etc.,wherein X is O, S, SO, SO2or NR2, etc.; R1is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13alkoxycarbonyl group, a carbamoyl group, etc.; Ar1and Ar2are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.
REFERENCES:
patent: 4672117 (1987-06-01), Abou-Gharbia et al.
patent: 6303614 (2001-10-01), Kennis et al.
patent: 6576640 (2003-06-01), Kennis et al.
patent: 0905136 (1999-03-01), None
patent: 62-070374 (1987-03-01), None
patent: 2001-515899 (2001-09-01), None
patent: WO 98/45297 (1998-10-01), None
Vippagunta et al, “Crystalline Solids”, Advanced Drug Delivery Reviews, vol. 48, 2001, pp. 3-26.
Gavezzotti, “Are Crystal Structures Predictable?”, Accounts of Chemical Research, vol. 27, 1994, pp. 309-314.
Kennis et al.: New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha2-antagonistic activity as potential antidepressant. Bioorg Med Chem Letters, 10:71-74, 2000.
Magid Abou-Gharbia, et al, “Psychotropic Agents: Synthesis and Antipsychotic Activity of Substituted β-Carbolines”, Journal of Medicinal Chemistry, vol. 30, No. 6, 1987, pp. 1100 to 1105.
Magid Abou-Charbia, et al, Antipsychotic Activity of Substituted γ-Carbolines, Journal of Medicinal Chemistry, vol. 30, No. 10, 1987, pp. 1818 to 1823.
Charles A. Harbert, et al, Neuroleptic Activity in 5-Aryletrahydro-γ-Carbolines, Journal of Medicinal Chemistry, vol. 23, No. 6, 1980, pp. 635 to 643.
Magid Abou-Gharbia, et al., “Psychotropic Agents: Synthesis and Antipsychotic Activity of Substituted β-Carbolines”, Journal of Medicinal Chemistry, 1987, pp. 1100-1105, vol. 30, No. 6.
Magid Abou-Charbia, et al., Antipsychotic Activity of Substituted γ-Carbolines, Journal of Medicinal Chemistry, 1987, pp. 1818-1823, vol. 30, No. 10.
Charles A. Harbert, et al., Neuroleptic Activity in 5-Aryltetrahydro-γ-carbolines, Journal of Medicinal Chemistry, 1980, pp. 635-643, vol. 23, No. 6.
International Search Report dated Jun. 7, 2005.
Amada Yuri
Kumagai Toshihito
Nakamura Toshio
Sekiguchi Yoshinori
Baek Bong-Sook
Kwon Brian-Yong S
Sughrue & Mion, PLLC
Taisho Pharmaceutical Co. Ltd.
LandOfFree
Cyclic amine compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amine compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amine compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4112154